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OBJECTIVES: To assess the use of angiotensin receptor blockers
(ARBs) in the European Union (EU) pediatric patients experienc-
ing essential hypertension. METHODS: This was a retrospective
analysis of the IMS MIDAS Prescribing Insight Medical data-
base. Projected prescription data for pediatric patients (<18
years) in the time period of October 2005 to September 2006
were analyzed. Five major European markets including France,
Germany, Italy, Spain and the UK were studied for the usage
of ARBs as either a monotherapy or ﬁxed-dose combination
therapy (FDC). Pediatric patients with essential hypertension
were identiﬁed using ICD-10 codes. The ATC classiﬁcation was
used to identify major classes of antihypertensives. During analy-
sis, special emphasis was placed on the 6–17 years age category,
as many ARBs were recommended in children above 6 years of
age. RESULTS: Out of 242,405 estimated pediatric patients with
hypertension, 222,033 (91.6%) were diagnosed with essential
hypertension. Out of 230,220 projected prescriptions dispensed
to these essential hypertensives, 76.2% were for patients in
the 6–17 years age group. In that age group, ARBs constituted
25.5% of the projected prescriptions with 10.6% in the form of
FDC of ARBs with hydrochlorothiazides (HCTz). Diuretics also
were used in 11.6% of the pediatric population in the age range
of 6–17 years. ARBs usage, either as a monotherapy or as a FDC
with HCTz, was higher in Italy (35.7%), France (30.9%)
and Spain (28.1%) but was lower in Germany (5.3%) and
non-existent in the UK. Valsartan-based and losartan-based
FDCs were commonly used in the age range of 6–17 years and
accounted for 39.1% and 13.9% of the projected prescription
volume in the ARB-FDC category, respectively. CONCLUSION:
In a majority of the key EU markets, pediatric hypertensive
patients in the age range of 6–17 years are regularly treated with
ARB monotherapy or FDC therapy, often without supportive
clinical efﬁcacy studies.
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OBJECTIVES: We will examine epidemiology of so-called outlier
payments-non-DRG bundled reimbursements for patients with
particular high hospital charges. In addition to describing the
incidence of outlier payments with each procedure, we will
explore the extent to which such payments vary across hospitals
and how they contribute to overall inpatient costs. METHODS:
Using the national Medicare claims database for 2002, we ﬁrst
identiﬁed all patients undergoing coronary artery bypass graft-
ing (CABG) (n = 165,226), lower extremity bypass surgery
(n = 43,886) and colectomy (n = 101,345). For each cancer type,
we identiﬁed total number of patients receiving outlier payments,
average outlier payments and total (Medicare) outlier payments.
We then assessed probability of having outlier payment for each
hospital, adjusting for potentially confounding patient character-
istics. RESULTS: For all three procedures, the proportion of
patients associated with outlier payments varied from 10%
(colectomy) to 13% (CABG). Average outlier payments were
considerable, ranging from $36,000 to over $59,000 per patient.
For these three procedures, outlier payments cost CMS approxi-
mately $835 million in 2002. Adjusting for confounding patient
characteristics did not change the variation in hospitals with
outlier payments. For all three procedures, the proportion of
hospitals with outlier payments 20 percent and higher varied
from 10.1% (colectomy) to 20.9% (CABG). CONCLUSION:
The individual hospitals appear to have differences in their
outlier costs and volatility of outlier costs when holding patient
factors are constant. Strong ﬁnancial incentives exists for
improving outcomes with inpatient surgery.
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OBJECTIVES: Is to analyze trends in prescription habits and
rational usage of cardiovascular medicines (CM) in Belgrade
population, as well as expenditure data regarding drug policy
changes and to make evaluation in terms of the most used
CM. METHODS: We used database from Public pharmacy
chain—Pharmacy “Belgrade” corresponding to population of
1.57 M, with conventional data grouping and database analysis.
All information on CM were based on prescriptions, which were
reimbursed by national Health Insurance Fund (HIF). The cal-
culations included: DDD methods (unit: DDD/1000 inhabitants/
day) and monetary cost for years level (2005–2006). RESULTS:
Expenditure of CM expressed as percentage of all used medicines
during two years, shows that a third of the overall ﬁnancial value
was spent in this group (33.13% in 2005; 35.33% in 2006).The
ﬁrst three groups of CM with highest ﬁnancial share (monetary
cost in % of all CM) are agents acting on the renin-angiotensin
system 49.72%, calcium channel blockers 24.16%, beta block-
ing system10.00% (2005); agents acting on the renin-angiotensin
system 47.77%, calcium channel blockers 22.99%, beta block-
ing system11.28% (2006). The usage of CM expressed in DDD
units reveals that in Belgrade population the most prescribed CM
is enalapril maleate during two years (71.22 in 2005; 74.89 in
2006). The biggest increase has been shown in the usage of
fosinopril sodium (from 5.44 in 2005 to 10.46 in 2006). CON-
CLUSION: Analysis and evaluation of the data has shown that
there had been increase in expenditure of CM in these periods.
The biggest increase is notiﬁed in the usage of fosinopril sodium
in both ﬁnancial values and DDD units, conducted by drug
policy changes (reimbursement list). Monitoring of the CM usage
in longer period can provide further useful information about
rational use of this group of medicines.
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OBJECTIVES: Coronary multidetector computed tomography
(MDCT) and myocardial perfusion imaging (MPI) are diagnostic
modalities used to identify patients with coronary artery disease
(CAD). We used Episode Treatment Groups™ (ETG) software,
an industry standard for combining health care billing informa-
tion into speciﬁc episodes of care, to examine CAD-related costs
and clinical outcomes of individuals who underwent diagnos-
tic evaluation by either MDCT or MPI. METHODS: Patients
without known CAD who underwent either MDCT or MPI as an
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